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ABSTRACT
Purpose To determine the immunogenicity of diphtheria
toxoid (DT) formulated in two types of vesicles following
transcutaneous immunization (TCI) of mice onto microneedle
array-treated skin.
Methods DT-containing cationic liposomes or anionic
surfactant-based vesicles were prepared by extrusion and
sonication. The physicochemical properties were characterized
in terms of size, ζ-potential, vesicle elasticity and antigen
association. TCI was performed by applying formulations onto
intact or microneedle array-pretreated mice skin, using cholera
toxin as an adjuvant. Subcutaneous and intradermal immuniza-
tions were as control. Immune responses were evaluated by
IgG and neutralizing antibody titers, and the immune-
stimulatory properties were assessed using cultured dendritic
cells.
Results Stable DT-containing cationic liposomes (∼150 nm)
and anionic vesicles (∼100 nm) were obtained. Incorporation
of Span 80 increased liposome elasticity. About 90% and 77%
DTwas associated with liposomes and vesicles, respectively. TCI
of all formulations resulted in substantial antibody titers only if
microneedle pretreatment was applied. Co-administration of
cholera toxin further augmented the immune responses of TCI.
However, vesicle formulations didn’t enhance the immunogenic-
ity on either intact or microneedle-treated skin and showed low
stimulatory activity on dendritic cells.
Conclusions Microneedle pretreatment and cholera toxin, but
not antigen association to vesicles, enhances the immunoge-
nicity of topically applied DT.
KEY WORDS choleratoxin.diphtheriatoxoid.microneedle
array.transcutaneousimmunization.vesicles
ABBREVIATIONS
Alum Adju-Phos®, colloidal aluminum phosphate
APCs antigen-presenting cells
CB(S) citrate buffer(ed saline)
CT cholera toxin
DC dendritic cell
DOTAP 1,2-dioleoyl-3-trimethylammonium-propane
chloride salt
DT diphtheria toxoid
GM-CSF granulocyte-macrophage colony-stimulating factor
HRP-GAM horseradish peroxidase conjugated goat
anti-mouse
i.d. intradermal
IL-4 interleukin-4
L-595 sucrose-laurate ester
LPS lipopolysaccharide
PB(S) phosphate buffer(ed saline)
PDI polydispersity index
PEG-8-L octaoxyethylene laurate ester
s.c. subcutaneous
SEC size exclusion chromatography
SPC soybean phosphatidyl choline
TCI transcutaneous immunization
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INTRODUCTION
Vaccination is a cost-effective way to fight infectious
diseases. Currently, most vaccines are administered by
subcutaneous (s.c.) or intramuscular injection. The prob-
lems with administration via these routes are that they are
painful, cause stress (especially in children), require trained
personnel and may lead to side effects. This results in
incomplete vaccination coverage and, hence, unnecessary
deaths from vaccine-preventable diseases. Consequently,
research is focused on alternative vaccine delivery through
oral (1), dermal (2), nasal (3) and pulmonary (4) routes.
Vaccination via the dermal route is of particular interest
since the skin is the biggest organ and is easily accessible.
Antigen-presenting cells (APCs) in the skin, in particular
the Langerhans cells in the epidermis and the dermal
dendritic cells (DCs) in the dermis, are the targets for
transcutaneous immunization (TCI), i.e. topical vaccine
application onto intact or pretreated skin. Epidermal
Langerhans cells usually represent about 1% of the total
epidermal cell population while covering 20% of the skin
surface (5). Upon contact with certain antigens together
with danger signals, e.g. skin barrier disruption or inflam-
mation, Langerhans cells and dermal DCs become activat-
ed. They capture antigens/pathogens, migrate to the
peripheral draining lymph nodes, process and present the
antigen to the naïve T cells and initiate immune responses (6).
However, a major hurdle is to overcome the stratum
corneum: the upper-most layer of the skin, which serves as
a barrier. This layer consists of corneocytes embedded in a
highly organized crystalline lamellar structure of the inter-
cellular lipid matrix. The unique arrangement of this layer
(15–20 μm thick in humans and thinner in mice) makes it
impermeable for macromolecules, including antigens (7).
In the 1970s, Gerstel and Place proposed the use of
microneedle arrays as a way to overcome this barrier in a
minimally invasive manner (8). However, it was not
employed in (trans)dermal drug delivery studies until about
10 years ago, when the technology for fabrication in micron
dimensions became available and cost-effective (9). After
the skin is treated with a microneedle array, tiny conduits
are formed transiently with little pain sensation. Antigens
are able to diffuse through the conduits to the APCs in the
epidermis and dermis (10). It has been shown previously
that microneedle array pretreatment leads to major improve-
ment in the immunogenicity of topically applied diphtheria
toxoid (DT) in mice (11). Other studies have also demon-
strated the promise of microneedle array-aided TCI:
Matriano et al. studied the dosing of a model antigen,
ovalbumin, and the kinetics and the magnitudes of antibody
titers induced in microneedle-mediated TCI in hairless
guinea pigs (12); Widera et al. investigated the influences of
important fabrication parameters, e.g. the needle length,
needle density, and covered skin area of the ovalbumin-
coated microneedle arrays, on the effectiveness of TCI (13).
Another approach to overcome the skin barrier in TCI is
to formulate antigens with vesicles. Elastic vesicles, consist-
ing of highly deformable bilayers, have been reported to be
able to improve transdermal drug delivery. These vesicle
formulations were applied non-occlusively as the transdermal
osmotic gradient has been reported to be the driving force of
the transport across the stratum corneum (14). For example,
Transfersomes® have been used successfully for a range of
small molecule drugs, including steroids, non-steroidal anti-
inflammatory drugs and local anesthetics (15–17), as well as
peptides and proteins, e.g. cyclosporin A and insulin (18,19).
Moreover, TCI with hepatitis B surface antigen-loaded
elastic liposomes and tetanus toxoid-loaded Transfersomes®
has been shown to elicit immune responses equivalent to
those produced by intramuscular injection of alum-adsorbed
antigens in mouse and rat, respectively (20,21). In our group,
elastic vesicles composed of surfactants have previously been
developed. After non-occlusive application on the skin,
vesicle structures were observed in the deeper layers of the
stratum corneum close to the stratum corneum-viable
epidermis junction. Enhanced delivery of lidocaine, rotigo-
tine and ketorolac was observed when the drug was
associated with vesicles and the formulation applied on the
skin in a non-occlusive manner (22–24). Therefore, there is a
potential for antigen-loaded vesicles as an effective formula-
tion for TCI.
In this study, for the first time, these two approaches—
microneedle pretreatment and antigen-loaded vesicle for-
mulations—were combined to assess their potential in TCI,
using DT (MW: 58 KDa; isoelectric point: 4.7) as an
antigen. Two types of vesicles have been included. Cationic
liposomes were made of soybean phosphatidylcholine (SPC)
and 1,2-dioleoyl-3-trimethylammonium-propane chloride
salt(DOTAP).Span80was incorporatedto increaseelasticity
of the vesicle bilayer (25). These liposomes in the absence or
presence of Span 80 are referred to as DT-Lip and DT-ELip
(DT Elastic Liposome), respectively. Characterization of
their physicochemical properties is reported in this study.
Surfactant-based vesicles were composed of sucrose-laurate
ester (L-595) and sodium bistridecyl sulfosuccinate (TR-70).
Octaoxyethylene-laurateester(PEG-8-L)wasusedtoincrease
the vesicle elasticity. This DT-containing vesicle formulation
has been developed and characterized previously and
referred to as DT-Ves in this paper (26). Selected formula-
tions were applied in TCI onto intact or microneedle-treated
skin of mice and compared with intradermal (i.d.) and s.c.
immunization. Their immunogenicity was evaluated by
146 Ding et al.measuring serum IgG (subtype) and neutralizing antibody
titers. Their immune-stimulatory properties were assessed in
vitro using human peripheral blood mononuclear cell-derived
immature DCs.
MATERIALS AND METHODS
Materials
SPC and DOTAP were kindly supplied by Lipoid GmbH
(Ludwigshafen, Germany). Diphtheria toxin (batch 79/1),
DT (batch 98/40, protein content 12.6 mg/ml by BCA
assay, 1 μg equals to approximately 0.3 Lf), horse anti-DT
and horseradish peroxidase (HRP) conjugated anti-DT
were provided by the Netherlands Vaccine Institute (NVI,
Bilthoven, the Netherlands). HRP-conjugated goat anti-
mouse (HRP-GAM) IgG (γ-chain specific), IgG1 (γ1-chain
specific) and IgG2a (γ2a-chain specific) were purchased
from Southern Biotech (Birmingham, US). Adju-Phos®
(alum) was obtained from Brenntag Biosector (Copenhagen,
Denmark). Chromogen 3, 3′,5 ,5 ′-tetramethylbenzidine
(TMB) and the substrate buffer were purchased from
Biosource B.V. (Nivelles, Belgium). Tween 20, lyophilized
bovine serum albumin, Folin Ciocalteu’s phenol reagent,
cholera toxin and Span 80 were ordered from Sigma-Aldrich
(Zwijndrecht, the Netherlands). Tween 80 was purchased
from Merck (Darmstadt, Germany). Ficoll and Percoll were
ordered from GE Healthcare (Eindhoven, the Netherlands).
Nimatek® (100 mg/ml ketamine), Rompun® (20 mg/ml
xylasine) and the injection fluid (0.9% NaCl) were obtained
from a local pharmacy. All other chemicals used were of
analytical grade, and all solutions were prepared with distilled
water.
Methods
DT Vesicle Formulation Preparation
The compositions of the DT vesicle formulations are listed
in Table I. The DT-Lip and DT-ELip were prepared using
the film rehydration and extrusion method. SPC, Span 80
and DOTAP, dissolved in chloroform, were mixed in an
appropriate ratio and formed a thin film at the bottom of
the flask using a rotary evaporator. Residual organic solvent
in the film was removed by 30 min nitrogen flow. The film
was rehydrated by 10 mM phosphate buffer (PB, pH 7.4,
7.7 mM Na2HPO4 and 2.3 mM NaH2PO4)o r1 0m M
citrate buffer (CB, pH 5.0, 4.0 mM H3C6H5O7 and
6.0 mM Na3C6H5O7) with or without saline (153 mM
NaCl, PBS or CBS) containing 1.5 mg/ml DT. The con-
centration of lipids in the buffer was 5% w/w. The resulting
dispersions were shaken at 200 rpm in the presence of glass
beads for 2 h at room temperature, followed by 2×15 s
tip sonication (20% energy output, Branson Ultrasonics,
Danbury, UK). The formulations were extruded
(LIPEX™ Extruder, Northern Lipids Inc., Canada) 3
times through a pair of polycarbonate filters with pore size of
200 nm and 3 times through another pair with pore size of
100 nm (Millipore, Amsterdam, the Netherlands). DT-Ves
were prepared and characterized in a previous study (26).
Briefly, the surfactants were dissolved in ethanol, while TR-
70 was dissolved in an ethanol/isopropanol mixture. After
mixing in an appropriate ratio, the organic solvents were
evaporated overnight in a vacuum centrifuge and rehydrated
with 10 mM CB (pH 5.0) containing 1.5 mg/ml DT.
Vesicles were formed after 3×5 s tip sonication (20% energy
output, Branson Ultrasonics). Subsequently, the pH of the
buffer was lowered to 4.5 by addition of 0.1 M HCl in order
to associate DT with the vesicles. The final concentration of
the surfactants in buffer was 10% w/w.
Size and ζ-Potential Measurements
The size and polydispersity index (PDI) of all formulations
were measured by dynamic light scattering using a
Zetasizer (Nano ZS, Malvern Ltd., United Kingdom). All
size measurements were performed at 25 °C at an angle of
173° between the laser and the detector. Before measuring,
all formulations were diluted in their corresponding buffer.
Formulations were measured at regular time points during
a period of 2 weeks after preparation to evaluate the colloidal
stability. The ζ-potential was measured by laser Doppler
electrophoresis using the same device. The formulations were
stored at 4 °C in between these measurements.
DT-Vesicle Association
To determine the DT-vesicle association ratios in the
formulations, size exclusion chromatography was per-
Table I DT-Loaded Vesicle Formulations
Buffer (pH) Components and molar ratio Abbreviated name
L-595:PEG-8-L:TR-70
CB (4.5) 5:5:1 DT-Ves
SPC:Span 80:DOTAP
PBS (7.4) 9:0:1 DT-Lip-PBS
PBS (7.4) 9:3:1 DT-ELip-PBS
PB (7.4) 9:0:1 DT-Lip
PB (7.4) 9:3:1 DT-ELip
CBS (5.0) 9:0:1 DT-Lip-CBS
CBS (5.0) 9:3:1 DT-ELip-CBS
CB (5.0) 9:0:1 DT-Lip-5
CB (5.0) 9:3:1 DT-ELip-5
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Sweden) column as previously described (26). Plain vesicles
(cationic liposomes or anionic surfactant vesicles) and free
DT in buffer solution served as controls to determine the
time window for fraction collection. Each formulation was
run with its corresponding buffer as mobile phase at a flow
speed of 0.40 ml/min. The recovery rate of DT after
SEC was determined by a modified Lowry-Peterson
protein assay, which separates the antigen from the
lipids/surfactants through a precipitation step and meas-
ures total protein content in each fraction (27). The
antigenicity of DT in each fraction was measured by ELISA,
usinghorseanti-DTserumandaHRP-conjugatedhorseanti-
DT, which measures the antigenicity of accessible DT in the
presenceofthe vesicle components. Datawere analyzed using
the principle of parallel-line analysis of the OD-log concen-
tration plots as described by Tierney et al.( 28).
To examine the status of DT-liposome association when
encountering physiological condition, the formulations were
eluted in SEC using PBS. The resulting liposome-associated-
DT fractions were further treated by 1% Triton X-100 to
disrupt the liposome structure and release the encapsulated
DT.The antigenicity ofDTinthese fractions was determined
by ELISA and compared to the corresponding fractions
eluted by the original buffers.
Microneedle Array and Applicator
The microneedle array used in this study was manufactured
from commercially available 30G hypodermic needles
(Becton Dickinson, Alphen a/d Rijn, the Netherlands) as
described previously (29). The needles were assembled as a
300 µm-long, 4×4 array on a polymer back plate with a
surface area of about 0.5 cm
2. The microneedles were
inserted into the skin at a speed of 3 m/s using an electric
impact applicator (11).
Evaluation of Vesicle Elasticity
The elasticity of the DT-loaded vesicles was evaluated by
extrusion through a modified Avanti Mini-Extruder®
(Avanti Polar Lipids Inc., Delfzyl, the Netherlands). This
method evaluates vesicle elasticity by comparing the
extruded volume of dispersions under constant pressure as
a function of time. In detail, the Mini-Extruder® was
mounted on a scaffold with both syringes standing
perpendicularly, donor above receptor. A polycarbonate
filter with pore size of 30 nm was inserted in between the
donor and acceptor syringes, and 1 ml of vesicle dispersion
was loaded in the donor syringe. A 1-kg weight was
mounted to generate a constant pressure of about 10 bar
on the piston of the donor syringe. Upon release of the
weight, the extruded volume of the dispersion in the receptor
syringe was recorded every minute over a 10-minute period.
This procedure was repeated two more times using freshly
prepared dispersions. The elasticity of vesicle membrane was
calculatedusingthefollowingformulaasreportedbyVanden
Bergh et al.( 30):
D ¼ J
rv
rp
 2
where, D, elasticity index of vesicle membrane; J,v o l u m eo f
dispersion extruded over 5 min; rv, size of vesicles; and rp,
pore size of the filter.
Immunization Protocol
Female BALB/c mice (H2d), 8 weeks old at the start of
the experiments, were purchased from Charles River
(Maastricht, the Netherlands) and maintained under
standardized conditions in the animal facility of the
Leiden/Amsterdam Center for Drug Research, Leiden
University. The study was conducted in conformity with
the Public Health Service Policy on use of laboratory
animals and had been approved by the Research Ethical
Committee of Leiden University.
Three immunization studies were carried out. Negatively
charged DT-Ves and positively charged DT liposome
formulations were applied on intact or microneedle-treated
skin in the first and second study, respectively. Formulations
were applied occlusively or non-occlusively, with the presence
or absence of CT as an adjuvant. Immunization of DT-Lip
via i.d. injection was carried out in the third study.
One day before immunization, the abdominal skin of
mice of TCI groups was shaved and rested for 24 h. During
immunization, mice were anesthetized by intraperitoneal
injection of 150 mg/kg ketamine and 10 mg/kg xylazine.
The shaved skin area was wiped with 70% ethanol. For
microneedle treatment, a skin fold was supported by
styrofoam and pierced using the microneedle array right
before the application of DT formulations. Seventy-μlD T
formulations containing 100 µg DT (and 100 µg CT if
applicable) per mouse were applied onto intact or treated
skin. The formulations were carefully spread over the entire
skin area of application, about 2 cm
2 restricted by a metal
ring. After 1 h occlusive or non-occlusive incubation, the
skin area was extensively washed with lukewarm tap water
and patted dry twice. In the third study, 30 µl DT-Lip or
DT solution containing 5 µg DT were given intradermally.
Five µg of DT adsorbed onto alum (DT-alum) in a 100 μl
saline suspension was administered by s.c. injection for all
three studies as a control. The DT-alum formulation was
prepared as previously described, and the adsorption of DT
to alum was between 70% and 80% (31). All DT formula-
tions were freshly prepared before each vaccination. Mice
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same skin region for the TCI groups) and sacrificed at day
56. Blood was sampled from the tail vein one day before
each immunization, and whole blood was collected from the
femoral artery during sacrifice. Cell-free sera were obtained
using MiniCollect® tubes (Greiner Bio-one, Alphen a/d
Rijn, the Netherlands) by centrifugation after clot formation
and stored at −80 °C until use.
Serum Antibody Assays
Serum IgG, IgG1 and IgG2a titers were determined by
ELISA. Briefly, ELISA plates (Microlon®, Greiner Bio-
one) were coated with DT at 4°C overnight. Two-fold
serial dilutions of serum samples were applied in the plates,
and the containing DT-specific antibodies were detected
by HRP-GAM IgG, IgG1 or IgG2a using TMB as
substrate. Antibody titers are expressed as the reciprocal
of the calculated sample dilution corresponding to half of
the maximum absorbance at 450 nm of a complete s-
shaped absorbance-log dilution curve. Mice with serum
sample unable to reach the half-saturated absorbance
value at the lowest (ten-fold) dilution were considered as
non-responders.
Protective immunity against diphtheria depends on the
presence of circulating neutralizing antibodies, evaluated
using Vero cell test: the WHO standard method to assess
the success of diphtheria vaccination, which relies on the
inhibition of a cytotoxic dose of diphtheria toxin (32). In
brief, after complement inactivation, two-fold serial dilutions
of serum samples were prepared with complete medium 199
(Gibco, Breda, the Netherlands) and applied to microtiter
plates (CELLSTAR®, Greiner Bio-one). Subsequently, 2.5×
10
−5 Lf diphtheria toxin was added to each well. After 2 h
incubation at 37°C for neutralization, Vero cell suspension
was added to each well. Covered with a plate sealer, Vero
cells were incubated at 37°C in 5% CO2 for 6 days. The end
point was taken as the highest dilution protecting the Vero
cells.
DC Maturation Study
Immature DCs were prepared from human peripheral
blood mononuclear cells, which were isolated by Ficoll-
Percoll density-gradient centrifugation on day 0. Monocytes
were separated from platelets due to their adherence to the
plastic surface (24 well plate for cell culture, Costar®,
Corning, New York, US) after incubation at 37°C for
60 min. The adherent cells were cultured for 6 days in
RPMI 1640, supplemented with 10% v/v fetal calf serum
(FCS, Biosource-Invitrogen, Breda, the Netherlands), 1%
glutamine, 100 U/ml penicillin and 0.1 mg/ml of streptomy-
cin, 250 U/ml granulocyte-macrophage colony-stimulating
factor (GM-CSF, Biosource-Invitrogen) and 100 U/ml
interleukin-4 (IL-4, Biosource-Invitrogen) at 37 °C with 5%
CO2 to differentiate into immature DCs. Medium was
refreshed at day 3. At day 6, the medium was replaced by
new medium containing GM-CSF and 2 μg/ml DT, either
free, mixed with CT or associated in liposomes or vesicles,
using lipopolysaccharide (LPS, from Escherichia coli,S i g m a )
as a positive control. Then DCs were incubated for 48 h at
37°C. Subsequently, DCs were washed 3 times with PBS
containing 1% w/v BSA and 2% v/v FCS and incubated for
30 min with a mixture of 20× diluted anti-HLADR-FITC,
anti-CD83-PE and anti-CD86-APC (Becton Dickinson) on
ice. Cells were washed again, and the expression of MHC II,
CD83 and CD86 was quantified using flow cytometry
(FACS Canto II, Becton Dickinson). The up-regulation of
these three surface markers by 50 ng/ml LPS was set as
100%. Live cells were gated based on forward and side
scatter. A minimum of 10,000 DC events were analyzed in
each experiment. The study was repeated using DCs from at
least three different donors.
Statistical Analysis
IgG (subtype) antibody titers were analyzed with two-way
ANOVA with Bonferroni post-test, and the neutralizing
antibody titers were analyzed using one-way ANOVA with
the same post-test. Other analyses were performed where
suitable as indicated. Statistical analysis was carried out
using Prism Graphpad, and a p value less than 0.05 was
considered to be significant.
RESULTS
Colloidal Properties of DT Vesicle Formulations
Particle size and ζ-potential of the DT vesicle formulations
are provided in Table II. Particle size and ζ-potential
measured at day 7 and day 14 were very similar to the
original values (data not shown), indicating good colloidal
stability for all formulations listed. Particle sizes of the
liposome formulations without Span 80 were smaller than
those in the presence of Span 80. Formulations prepared by
extrusion method show lower PDI than those prepared by
sonication method.
Association of DTwith the Vesicles
The DT-Ves was characterized previously (Table II). The
majority of DT was associated with vesicles when the pH of
the buffer was lowered to 4.5 and dissociated when pH was
increased to 7.4. The association and dissociation were not
influenced by the ion strength of the buffer.
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pared in PB at pH 7.4 and CB at pH 5.0, high DT-
liposome association was observed. After SEC of DT-Lip
and DT-ELip, nearly all protein content was recovered
from the liposome-associated DT fractions, whereas for
DT-Lip-5 and DT-ELip-5, the recovery from the liposome-
associated DT fraction was about 30% (Fig. 1a). However,
when prepared in PBS and CBS instead, the liposome-
associated DT in all four formulations appeared to be lower
than 15% (data not shown). This indicates that ionic strength
and pH of the buffer play a prominent role in the antigen-
liposome association. Formulations prepared in PB and CB
were selected for further studies due to higher DT-liposome
association.
When detected with ELISA, the percentages of DT
antigenicity in the free-DT fractions were similar to those of
protein content, while the antigenicity from the liposome-
associated DT fractions was much less (Fig. 1b). This
significant loss of DT antigenicity is probably due to the
shielding effect of the liposome on the encapsulated DT.
Selected formulations were eluted with PBS (pH 7.4) in
SEC to examine the status of DT-liposome association in
physiological condition. DT antigenicity of the resulting
fractions were measured and compared with those eluted
by CB/PB (Fig. 1c and d). These figures show that part of
the liposome-associated DT, probably attached to the
liposome surface, was dissociated from the liposomes.
When the liposome-associated DT fractions were further
treated with Triton X-100, increased DT antigenicity was
detected, and the overall recovery rate of DT antigenicity
was increased to about 80%, comparable to the control
group. This increased DT antigenicity was previously
shielded by liposome and represents the encapsulated
DT under physiological condition (Table II). The DT-
encapsulation ratio in PB at pH 7.4 was significantly higher
than that in CB at pH 5.0 (p<0.001, t-test), most likely due
to the higher negative charge of DT at pH 7.4, which
facilitates the electrostatic interaction between DT and the
liposome components.
Elasticity of the DT-Loaded Vesicles
The extruded volumes of DT-loaded vesicle formulations
and the calculated elasticity indices are shown in Fig. 2a
and b, respectively. The unloaded surfactant vesicles
showed relatively high elasticity. However, it was dramat-
ically reduced by the loading of DT. When 0.2 mg/ml or
more DT was incorporated, the dispersions could hardly be
extruded, similar to the rigid DT-Lip. On the other hand,
DT-ELip retained its elasticity and can be extruded through
filter with 30 nm pore size. The particle size of DT-ELip
(∼175 nm) was much larger than that of empty vesicles
(∼100 nm). For this reason, even though its extrusion speed
was slightly slower than the empty surfactant vesicles, it shows
the highest elasticity index.
Analysis of Antibody Titers Induced in TCI
DT-Loaded Anionic Surfactant Vesicles
First, TCI was performed by applying free DT and DT-Ves
onto microneedle-treated or intact skin using CT as an
adjuvant. The serum IgG titers after prime, the first boost
and the second boost and the neutralizing antibody titers
after the second boost through occlusive application are
provided in Fig. 3. Non-occlusive application of the same
formulations was also studied, and no significant difference
was found compared to the corresponding occlusive groups.
For clarity, only data from non-occlusive application of DT-
Ves onto intact skin are shown in Fig. 3b. Pretreatment of
the skin using the microneedle array improved the antibody
responses drastically for both free DT and DT-Ves (Fig. 3a
vs. b). The presence of CT further potentiated the IgG titers
for DT-Ves (p>0.05, p<0.001 and p<0.001 after prime, the
firstboostandsecondboost,respectively)andforfreeDT(p<
0.05, p<0.001 and p<0.05 after prime, the first boost and
second boost, respectively). For DT-Ves, IgG titers were
very close to those induced by s.c. DT-alum after the second
boost (p>0.05), whereas for free DT, comparable IgG titers
Table II Characterization of DT Vesicle Formulations. Data Shown are Mean ± SD of Three Different Batches.
Abbreviated name Size (nm) PDI ζ-potential (mV) Association %
a (Lowry-Peterson) Encapsulation %
b (ELISA) in PBS
DT-Ves 101±6 0.28±0.03 −77.3±3.0 76.8±2.9 –
DT-Lip 164±2 0.23±0.02 24.5±1.4 86.7±3.9 36.0±4.5
c
DT-ELip 175±3 0.21±0.03 24.4±0.6 86.7±5.1 46.9±4.3
d
DT-Lip-5 124±9 0.12±0.02 24.6±2.0 29.9±4.0 14.4±4.0
DT-ELip-5 149±3 0.11±0.01 24.8±1.1 40.0±4.3 13.0±3.3
aAssociated DT: includes the surface-attached DT, bilayer-intercalated DTand the liposome-encapsulated DT
bEncapsulated DT: DTreleased upon Triton x-100 treatment, detected by ELISA
cSignificantly higher than those of DT-Lip-5 (p<0.001, t-test)
dSignificantly higher than those of DT-ELip-5 (p<0.001)
150 Ding et al.were obtained from the first boost on (p>0.05). Sur-
prisingly, DT-Ves formulations did not induce higher IgG
titers than free DT through either occlusive or non-
occlusive application (p>0.05 for all three time points).
The IgG1 followed the IgG and showed slightly lower
titers with similar trend, while the IgG2a titers were much
less developed with many non-responders (data not
shown).
The neutralizing antibody titers showed the same trend
as the IgG titers after the second boost (Fig. 3c). The
presence of CT enhanced the titers of both free DT and
DT-Ves (p<0.001 for both). The differences between free
DT and DT-Ves are more pronounced. DT-Ves induced
lower titers than DT (p<0.001 and p<0.05 for with and
without CT, respectively). The titers induced by DT-Ves
with CT were lower than those of s.c. DT-alum (p<0.001),
whereas for IgG titers, the difference was not significant. In
the presence of CT, free DT induced comparable neutral-
izing antibody titers to those of s.c. DT-alum, the same as
the IgG titers.
In TCI on intact skin, free DT and DT-Ves resulted in
neither substantial antibody responses nor detectable
neutralizing antibody titers. DT-Ves did not improve the
immune responses of free DT, either.
As DT is released quickly from DT-Ves at pH 7.4, and
the negative surface potential may reduce the interactions
between vesicles and the cell membranes of APCs, positively
charged vesicles were included in our studies. Initially, we
focused on developing positively charged, DT-loaded, surfac-
tant vesicles to obtain high DT-vesicle association at pH 7.4.
However, by replacing TR-70 with DOTAP or dimethyl
dioctadecyl ammonium as the charge inducer, stable for-
mulations could not be obtained. The cationic liposome
formulations were developed instead, in which considerable
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Fig. 1 DT-liposome association in formulations prepared in CB or PB. The liposome-associated DT and free DT were separated through SEC
fractionation of formulations by their corresponding buffers and determined with Lowry-Peterson protein assay (a) and ELISA (b); free DT in PB and CB
served as control. DT liposome formulations prepared in CB and PB were eluted in SEC with PBS (referred to as “eluted by PBS,” c and d). The resulted
liposome-associated DT fractions were further treated with 1% Triton X-100 to release the encapsulated DT, and both were measured with ELISA
(referred to as “treated by Triton X-100”). Data are shown as mean + SD of three different batches.
Transcutaneous Immunization Using Vesicles and a Microneedle Array 151amount of DT has stable association with liposomes when
diluted in PBS.
DT-Loaded Cationic Liposomes
On microneedle-treated skin, TCI was performed using
DT-Lip, DT-Lip-5 and DT-ELip using CT as an adjuvant.
Only occlusive application was performed, as no differences
between occlusion and non-occlusion were observed in the
study of DT-Ves. Serum IgG and neutralizing antibody titers
are provided in Fig. 4. The presence of CT potentiated the
IgG titers and neutralizing antibody titers of DT-Lip
significantly (p<0.001 for IgG titers after the first and second
boost, and the neutralizing antibody titers, Fig. 4b and c).
However, the DT liposome formulations did not induce
higher immune responses than free DT, either. DT-ELip
resulted in lower IgG titers after prime and the first boost,
and lower neutralizing antibody titers after the second boost
as compared to free DT (p<0.01, p<0.001 and p<0.01,
respectively). Only after the second boost, it induced a
comparable level of IgG titers as free DT (p>0.05), higher
than those of DT-Lip-5 and DT-Lip (p<0.05 and p<0.001,
respectively, Fig. 4a). DT-Lip and DT-Lip-5 induced lower
IgG titers than free DT at all three time points (p<0.05,
p<0.001 and p<0.001, respectively, Fig. 4a)a n dl o w e r
neutralizing antibody titers (p<0.001, Fig. 4c). Similar
titers induced by DT-Lip and DT-Lip-5 indicate that the
immunogenicity is not sensitive to the different DT-
liposome association ratios (Fig. 4a). Same as the study
of DT-Ves, the IgG1 titers of DT liposome formulations
followed the IgG titers and showed a similar trend. The
IgG2a titers were much less developed (data not shown).
As for DT-Ves, the loss of vesicle elasticity by the loading
of DT was also suspected to account for its low immuno-
genicity on intact skin, TCI of DT-ELip on intact skin was
included because of its superior elasticity. However, the
IgG levels induced were low and comparable to those of
free DT and DT-Ves (Fig. 4a vs. Fig. 3), and occlusive and
non-occlusive applications showed no difference in serum
IgG titers (Fig. 4a).
Analysis of Antibody Titers Induced via i.d.
Immunization
All the data suggest that vesicle formulations do not
improve the immune response in TCI. To study whether
differences in delivery efficiency across the skin barrier play
a role, DT-Lip and free DT were administered via i.d.
injection. The resulting serum IgG, IgG1, IgG2a and
neutralizing antibody titers are shown in Fig. 5. The IgG,
IgG1 and neutralizing antibody titers from free DT and
DT-Lip were not significantly different. Unlike TCI, i.d.
immunization of free DT and DT-Lip induced substantial
IgG2a titers. Interestingly, DT-Lip induced a faster increase
in IgG2a titers than free DT, and significantly higher
IgG2a titers were found after the first and the second boost
(Fig. 5b, p<0.001, two-way ANOVA), suggesting immune
modulation to a more Th1-biased response.
DC Maturation upon Contact with DT-Loaded Vesicles
To circumvent the complicated factors in delivery efficiency
across the skin barrier, the direct stimulatory effects of DT
formulations on the maturation of DCs were investigated
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Fig. 2 The vesicle elasticity measured with the extrusion method. DT vesicle formulations were extruded through polycarbonate filters with pore size of
30 nm under a constant pressure of 10 bar. The extruded volumes of these dispersions were recorded once per minute during 10 min (a). Particle sizes
of the dispersions were measured by dynamic light scattering, and the elasticity indices were calculated using the extruded volumes after 5 min (b). Data
shown are mean + SD of three batches.
152 Ding et al.in vitro. The up-regulation of the surface markers, MHC II,
CD83 and CD86, was determined after culturing immature
DCs in the presence of the DT formulations (Fig. 6). DT
alone had no effect on the surface markers tested. CT
showed the most potent stimulation to the immature DCs.
It significantly up-regulated MHC II expression to levels
higher than LPS and at the same time moderately enhanced
those of CD86 as compared to free DT (p<0.001 and p<
0.01, respectively, one way ANOVA). DT-Ves, DT-Lip and
DT-ELip did not show significant up-regulation to all three
surface markers as compared to free DT.
DISCUSSION
In the current study, stable DT-loaded liposome formula-
tions were prepared and characterized in terms of their
particle size, ζ-potential, degree of DT-vesicle association
and vesicle elasticity. Two types of DT vesicle formulations,
cationic liposomes and anionic surfactant vesicles, were
studied in TCI, and the skin was either pretreated with
microneedle arrays or left intact. Pretreatment with the
microneedle array and co-administration with CT improved
the immune responses of all of the formulations dramatically.
However, the immunogenicity was not improved further by
using vesicle formulations.
Initially, surfactant vesicles were chosen to formulate DT
for TCI as a vaccine delivery system, as they have been
shown to enhance the transport of small molecule drugs
across human skin. Evidence for an exceptional interaction
between these vesicles and human skin in vivo was obtained
by freeze fracture electron microscopy and Fourier trans-
form infrared studies (24,33); vesicular structures were
observed in the deep layers of the stratum corneum after
1 h non-occlusive application. However, there was no
evidence of vesicle material in the viable epidermis. The
same vesicle system was employed for DT delivery in the
current study. However, on intact skin, no substantial
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Fig. 3 DT-specific IgG titers and neutralizing antibody titers after TCI of DT-Ves and free DT using CT as an adjuvant. Formulations were applied
occlusively (unless specified in b) on microneedle-treated (a) or intact skin (b) at day 0, 21 and 42; s.c. injection of DT-alum served as control. Sera were
collected after prime, the first boost and the second boost (day 20, 41 and 55), and IgG titers were determined with ELISA. Data shown as mean + SD (n=8).
Non-responders were given an arbitrary log-value of 1. Neutralizing antibody titers of TCI on microneedle-pretreated skin after the second boost were
evaluated with Vero cell test. An arbitrary log-value of 0 was given when titers were below detection limit (c). Neutralizing antibody titers from intact skin were
all below detection limit and therefore not shown (*: p<0.05, **: p<0.01, ***: p<0.001).
Transcutaneous Immunization Using Vesicles and a Microneedle Array 153immune response was induced by DT-Ves and free DT,
following either occlusive or non-occlusive application. The
comparable immunogenicity of DT-Ves and free DT on
intact skin indicates that vesicles do not efficiently transport
the antigen across the stratum corneum. As this could be
due to fast DT release from vesicles at pH 7.4 and the loss
of vesicle elasticity when DT is incorporated, it was decided
to prepare DT-ELip, which showed both association of DT
with the vesicles/liposomes at pH 7.4 and an increased
elasticity when DT is associated with the liposomes.
However, in the subsequent in vivo immunization study,
DT-ELip did not enhance the immunogenicity of topically
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Fig. 4 DT-specific IgG titers and neutralizing antibody titers induced by DT liposome formulations in TCI. Formulations were applied occlusively on
microneedle-treated skin (unless specified in a) at day 0, 21 and 42; s.c. injection of DT-alum as control. Sera were collected after prime, the first boost
and the second boost (day 20, 41 and 55), and IgG titers were determined with ELISA (a and b). Data shown as mean + SD (n=8). Non-responders
were given an arbitrary log-value of 1. Neutralizing antibody titers after the second boost were evaluated with Vero cell test (c). An arbitrary log-value of 0
was given when titers were below detection limit (*: p<0.05, **: p<0.01, ***: p<0.001).
154 Ding et al.applied DT on intact and microneedle-pretreated skin. As
the composition of the Span liposomes is very similar to
that of Transfersomes
® used in TCI for hepatitis B surface
antigen and gap junction protein, the outcome of our
studies is in contrast to those reporting that ultradeformable
vesicles induce potent immune responses on intact skin after
non-occlusive application (20,34). In our hands, elastic
vesicles enhance the transport of small molecules across the
skin (22–24), but do not improve the immunogenicity of
topically applied antigens, e.g. DT. In addition, there is no
difference between occlusive and non-occlusive application
for the elastic liposomes. Therefore, the osmotic gradient
does not seem to play a central role as a driving force for
antigen diffusion using these formulations.
To facilitate the transport of antigens into the viable
epidermis, inclusion of skin barrier disruption methods, e.g.
microneedle array pretreatment, tape striping or electro-
poration etc., appears to be crucial (35). Microneedle
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Fig. 5 DT-specific IgG subtype antibody titers and neutralizing antibody titers after i.d. injection of DT-Lip and free DT. Vaccination was performed at day
0, 21 and 42; s.c. injection of DT-alum was as control. Sera were collected after prime, the first boost and the second boost (day 20, 41 and 55), and IgG,
IgG1 and IgG2a titers were determined with ELISA (a, b and c). Data shown as mean + SD (n=8). Non-responders were given an arbitrary log-value of
1. Neutralizing antibody titers after the second boost were evaluated with Vero cell test (d). An arbitrary log-value of 0 was given when titers were below
detection limit (***: p<0.001).
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Fig. 6 Stimulatory effects of DT formulations on immature DCs as
indicated by the up-regulation of the surface markers MHC II, CD83 and
CD86. The level of these three surface markers induced by 50 ng/ml LPS
was set as 100%. The culture medium has a basal level of stimulation to
the DCs as it contains GM-CSF . The final concentrations of each formulation
component in culture medium were DT (2 μg/ml), DT+CT (2 μg/ml DT
with 2 μg/ml CT), DT-Lip and DT-ELip (2 μg/ml DTwith 70 μg/ml total
lipids), DT-Ves (2μg/ml DTwith140 μg/ml total surfactants). Datashown are
mean + SD (n≥3).
Transcutaneous Immunization Using Vesicles and a Microneedle Array 155pretreatment has been shown to enhance the transcutaneous
transport significantly. Henry et al. demonstrated four orders
of magnitude increase in permeability for calcein and BSA
through human epidermis in vitro after pretreatment with a
microneedle array of 150 μm needle length (9), while
Verbaan et al. showed penetration of 72 kDa dextran across
microneedle-pretreated human skin in vitro using 300 μm
long microneedle array (29). In the current study, the
improved immunogenicity provided by the microneedle
pretreatment may be attributed not only to enhanced antigen
transport across the skin barrier, but also to the danger
signals (IL-1α, IL-1β, GM-CSF and TNF-α released from the
surrounding keratinocytes) caused by the skin barrier
disruption, which sensitize and mobilize the skin APCs (36).
The induced immune response depends on both the
permeation along the conduits and the interaction of the
formulation with the skin APCs. I.d. vaccination was
performed to exclude the influence of transport along the
conduits on the immune responses. In addition, the DC
study provided equal contact of DT to the APCs in vitro.
I.d. vaccination of free DT and DT-Lip induced similar
IgG1 and neutralizing antibody titers. This indicates that
liposomes do not stimulate maturation of DCs. When com-
paring i.d. vaccination with TCI on microneedle-pretreated
skin, where the same dose of DT in DT-Lip induced sig-
nificantly lower immune response than free DT, it is clear
that the transport of DT-loaded liposomes along the
conduits is one of the limiting factors. This might be due
to non-specific bindings of the positively charged liposomes
to other cell membranes and negatively charged intercellular
proteins, as reported by Yan et al.( 37). As the negatively
charged vesicles also reduced the immune response, it seems
that a lower diffusion rate along the conduits may also
p l a yar o l e .A na p p l i c a t i o np e r i o dl o n g e rt h a n1hm a y
enhance the diffusion and improve the immune responses
in TCI, as the conduits formed by the microneedles remain
open for at least a few hours as reported by Bal et al.( 38)a n d
Banga et al.( 39).
In TCI on microneedle-pretreated skin, it is notable that
free DT induced faster IgG development than DT liposome
formulations (Fig. 4). Most probably the soluble antigen
diffuses faster along the conduits into the skin and arrives
earlier in the viable layers and the peripheral draining
lymph nodes. The role of direct lymphatic drainage of
free antigen and the subsequent capture by blood-
derived, lymph node-resident DCs for presentation to T
cells has been highlighted in recent studies (40–43).
So far, a DT/CT mixture, soluble antigen with soluble
adjuvant, is the most immunogenic formulation in TCI on
microneedle-pretreated skin. CpG ODN also demonstrated
potent immune potentiation and modulation properties in
our previous TCI study of DT (44). Moreover, the alum-
adsorbed DT, big particles of several microns, reduced IgG
titers dramatically and diminished the neutralizing antibody
titers to undetectable level when applied on microneedle-
treated skin (data not shown). Therefore, including other
potent and soluble adjuvants is one of the first directions for
further optimization of TCI formulations. Antigen-adjuvant
conjugates and antigen-adjuvant fusion constructs may also
be potential candidates. Furthermore, it has been reported
that following i.d. injection in mice, 20 nm particles are
taken up into the lymphatics more readily than 45 or
100 nm particles and are retained in the lymph nodes for a
longer time (up to 120 h) (45). These ultra-small particles as
well as some specific types of vesicles, e.g. ISCOMS, virus-
like particles and surface-modified liposomes (46,47), hold
promise in TCI when combined with microneedle array
pretreatment. Last but not least, instead of relying on passive
diffusion following microneedle treatment, the development
of a microneedle array through which the vaccine formula-
tion could be injected would provide more precise dose
control and improve the vaccination efficiency.
CONCLUSION
We have demonstrated in the current study that the
microneedle array pretreatment of the skin and co-
administration of CT significantly enhances the immuno-
genicity of topically applied DT. However, formulating the
antigen with vesicles, rigid or elastic, anionic or cationic,
applied occlusively or non-occlusively, does not further
improve the immune responses.
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